Table 2

The outcomes reporting for clinical trials of antiarrhythmic treatment (N=88)

Domains/outcomesOutcomes reporting (n)OMIs/definitions (n)Measurement time point (n)
 All-cause mortality1108
 Cardiovascular death503
Vascular outcomes
 Non-central nervous system embolism602
Cardiac outcomes
 ECG outcomes18214
 Time to conversion715
 Mean sinus rhythm maintenance time116
 Time to first AF recurrence413
 Conversion to sinus rhythm26112
 Sinus rhythm maintenance1536
 AF recurrence3622
 AF progression623
 AF controlling rate202
 AF persistence1125
 Number of electrical cardioversion101
 Number of taking antiarrhythmic drugs101
 Number of undertaking ablation101
 Ultrasonic cardiogram39110
 Heart rate21214
 NYHA classification grading of cardiac function312
 Myocardial infarction202
 Ventricular arrhythmia211
 Heart failure202
 Blood pressure2006
Blood and lymphatic system outcomes
Nervous system outcomes
 Haemorrhagic stroke1106
 Ischaemic stroke604
Immune system outcomes
 Solubility P-selectin111
 Connective tissue growth factor111
Endocrine outcomes
 Renin, AngII411
Hepatobiliary outcomes
Renal and urinary outcomes
 Serum creatinine103
 Urine sodium101
Metabolism and nutrition outcomes
 Serum homocysteine313
General outcomes
 Body mass index101
 Mean drug onset time101
 Therapeutic compliance105
Withdrawal from treatment
 Withdrawal from treatment101
Physical functioning
 6 Min walk test111
Adverse events/effects
 Adverse events/side effects2608
Resource use: Hospital
 All-cause hospitalisation503
 Cardiovascular hospitalisations614
 Hospital length of stay100
 Readmission rates101
  • ALT, alanine aminotransferase; ANP, atrial natriuretic peptide;APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CRP, C reactive protein; ECG, electrocardiogram; FIB, fibrinogen; HDL-C, High density lipoprotein cholesterol; IFN-γ, interferon-γ; IL, interleukin; LDL-C, low-density lipoprotein cholesterol; MMP2, matrix metalloproteinase-2; NT-proBNP, N terminal pro B type natriuretic peptide; NYHA, New York Heart Association; PT, prothrombin time; TC, total cholesterol; TG, total triglyceride; TIMP2, tissue inhibitor of metalloproteinase 2; TNF-α, tumour necrosis factor-α; TSH, thyroid stimulating hormone; TT, thrombin time.